Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLSD 
Clearside Biomedical Inc (CLSD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CLSD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $60
1 Year Target Price $60
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -79.41% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.69M USD | Price to earnings Ratio - | 1Y Target Price 60 |
Price to earnings Ratio - | 1Y Target Price 60 | ||
Volume (30-day avg) 7 | Beta 2.11 | 52 Weeks Range 3.32 - 24.75 | Updated Date 09/17/2025 |
52 Weeks Range 3.32 - 24.75 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-18 | When - | Estimate -0.1029 | Actual -0.1 |
Profitability
Profit Margin - | Operating Margin (TTM) -725.2% |
Management Effectiveness
Return on Assets (TTM) -55.45% | Return on Equity (TTM) -1310.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9842454 | Price to Sales(TTM) 4.49 |
Enterprise Value 9842454 | Price to Sales(TTM) 4.49 | ||
Enterprise Value to Revenue 2.36 | Enterprise Value to EBITDA -2.84 | Shares Outstanding 5234020 | Shares Floating 4540935 |
Shares Outstanding 5234020 | Shares Floating 4540935 | ||
Percent Insiders 12.88 | Percent Institutions 14.87 |
Upturn AI SWOT
Clearside Biomedical Inc
Company Overview
History and Background
Clearside Biomedical Inc. was founded in 2011. The company focuses on developing therapies to restore and preserve vision in patients with sight-threatening diseases. It utilizes its SCS Microinjector platform to access the suprachoroidal space (SCS).
Core Business Areas
- Therapeutic Development: Focuses on the development and commercialization of therapies for retinal diseases delivered via the suprachoroidal space (SCS).
- SCS Microinjector Platform: Develops and commercializes the SCS Microinjector, a device designed for precise drug delivery to the back of the eye.
Leadership and Structure
George Lasezkay, MD, is the CEO of Clearside Biomedical. The company has a standard organizational structure with departments focused on research and development, clinical operations, regulatory affairs, commercialization, and finance.
Top Products and Market Share
Key Offerings
- XIPERE (triamcinolone acetonide injectable suspension): XIPERE is the first and only FDA-approved therapy for suprachoroidal administration for the treatment of macular edema associated with uveitis. Competitors include standard intravitreal injections of corticosteroids or anti-VEGF agents. Exact market share data is limited but it is growing. Revenue data would need to be obtained from financial reports.
- SCS Microinjector: The SCS Microinjector is a platform technology for delivering drugs to the suprachoroidal space (SCS) in the eye. It is used for XIPERE and potentially other future SCS-delivered therapies. It is a key enabling technology, rather than a standalone revenue generator. Competitors for drug delivery platforms include other injection technologies and delivery systems from companies like REGENXBIO, Adverum Biotechnologies, and Kodiak Sciences.
Market Dynamics
Industry Overview
The ophthalmic therapeutics market is a large and growing market. Key drivers include an aging population, increased prevalence of diabetes, and advances in drug delivery technologies.
Positioning
Clearside Biomedical is positioned as an innovator in drug delivery to the back of the eye via the suprachoroidal space. Their competitive advantage lies in their SCS Microinjector platform and XIPERE's unique delivery method. They differentiate themselves through targeted delivery and potentially reduced side effects compared to traditional intravitreal injections.
Total Addressable Market (TAM)
The global ophthalmic drug market is estimated to be over $40 billion. Clearside is positioned to capture a portion of this market, primarily within the retinal disease segment. TAM for macular edema associated with uveitis is a subset of the larger market. Clearside's positioning allows them to potentially expand to other retinal diseases using the same delivery system.
Upturn SWOT Analysis
Strengths
- FDA-approved product (XIPERE)
- Proprietary SCS Microinjector platform
- Targeted drug delivery to the suprachoroidal space
- Experienced management team
- Potential for expanded applications of SCS platform
Weaknesses
- Reliance on a single approved product
- Limited commercialization experience
- Potential for competition from established intravitreal therapies
- Need for additional clinical trials for other indications
- Market adoption of new route of administration (SCS) needs to be proven
Opportunities
- Expanding XIPERE's indications to other retinal diseases
- Partnering with other pharmaceutical companies to develop SCS-delivered therapies
- Developing new SCS Microinjector-compatible formulations
- Entering new geographic markets
- Addressing unmet needs in retinal disease treatment
Threats
- Competition from established intravitreal therapies (anti-VEGF, corticosteroids)
- Regulatory hurdles and clinical trial risks
- Reimbursement challenges for XIPERE
- Potential safety concerns associated with SCS delivery
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- REGN
- VRTX
- ALNY
- LLY
Competitive Landscape
Clearside's competitive advantage is its unique drug delivery platform. However, they face competition from larger, more established pharmaceutical companies with broader product portfolios. They need to demonstrate the clinical and economic benefits of their SCS platform to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Growth has been largely dependent on the development and commercialization of XIPERE. Historical growth has been variable.
Future Projections: Future growth depends on successful commercialization of XIPERE, expansion of indications, and potential partnerships. Analyst estimates vary.
Recent Initiatives: Focusing on expanding commercial reach of XIPERE, exploring new applications of the SCS Microinjector, and partnering with other companies.
Summary
Clearside Biomedical possesses a unique drug delivery system that is generating promising results. Its success largely depends on XIPERE's commercial success and expanded indications. They must be vigilant about competition from established treatments and focus on demonstrating the advantages of their platform. The company is considered a niche player in a big market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearside Biomedical Inc
Exchange NASDAQ | Headquaters Alpharetta, GA, United States | ||
IPO Launch date 2016-06-02 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://clearsidebio.com |
Full time employees 32 | Website https://clearsidebio.com | ||
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.